Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 06 Mar 2026
Agenda for the March 2026 PBAC meeting (4 March 2026)
6 March 2026 - The Department of Health has published an updated agenda for the March 2026 PBAC agenda (version ...
Posted by Michael Wonder on 06 Mar 2026
HLS Therapeutics announces Nilemdo (bempedoic acid) is now available in Canada for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease
5 March 2026 - HLS Therapeutics today announced the commercial launch of Nilemdo (bempedoic acid) in Canada. Nilemdo is now available ...
Posted by Michael Wonder on 06 Mar 2026
Roche's Columvi, Takeda's Fruzaqla pass first review for Korea insurance coverage
5 March 2026 - Roche's DLBCL treatment Columvi (glofitamab) and Takeda's metastatic colorectal cancer treatment Fruzaqla (fruquintinib) have cleared the ...
Posted by Michael Wonder on 05 Mar 2026
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma
5 March 2026 - Today, the FDA approved teclistamab (Tecvayli, Janssen Biotech) in combination with daratumumab hyaluronidase-fihj for adult patients ...
Posted by Michael Wonder on 05 Mar 2026
New multi-indication PBS listing for two immunotherapy treatments from March 2026
1 March 2026 - Bristol Myers Squibb Australia confirms that Opdivo (nivolumab) and Yervoy (ipilimumab) will be listed on the ...
Posted by Michael Wonder on 05 Mar 2026
Hemab Therapeutics receives FDA breakthrough therapy designation for sutacimig in Glanzmann thrombasthenia
5 March 2026 - Sutacimig has potential to become a first in class prophylactic treatment for Glanzmann thrombasthenia, an inherited serious ...
Posted by Michael Wonder on 05 Mar 2026
PDUFA action date for Hansa Biopharma's imlifidase BLA set for 19 December 2026
4 March 2026 - If approved, imlifidase will be the first treatment to address highly sensitised patients awaiting kidney transplantation. ...
Posted by Michael Wonder on 05 Mar 2026
Dying father pleads for cancer drug subsidy to ‘keep being a dad’
5 March 2026 - A North Queensland mother has travelled to Canberra to beg the Federal Government to save her ...
Posted by Michael Wonder on 05 Mar 2026
Priovant announces FDA acceptance and priority review of new drug application for brepocitinib in dermatomyositis
3 March 2026 - Priovant Therapeutics today announced that the US FDA has accepted its new drug application for brepocitinib for ...
Posted by Michael Wonder on 05 Mar 2026
New proposal aims to reduce complications following a stem cell transplant
5 March 2026 - People who have just had a stem cell transplant could be better protected from a serious ...
Posted by Michael Wonder on 04 Mar 2026
Affinia Therapeutics granted FDA fast track designation for AFTX-201 as a treatment for people living with BAG3-associated dilated cardiomyopathy
4 March 2026 - Affinia Therapeutics today announced that the US FDA has granted fast track designation for AFTX-201, a potential ...
Posted by Michael Wonder on 04 Mar 2026
Problems in study implementation: It often affects patient reported outcomes.
2 March 2026 - Patient-reported outcomes are of great importance for the evaluation of new drugs. However, these outcomes are repeatedly ...
Posted by Michael Wonder on 04 Mar 2026
Boryung adds Xpovio to blood cancer portfolio under Antengene license deal
4 March 2026 - Boryung said Wednesday that it has signed a license in deal with Antengene, a Chinese pharmaceutical ...
Posted by Michael Wonder on 04 Mar 2026
J&J Korea receives reimbursement for Balversa in urothelial carcinoma
3 March 2026 - Johnson & Johnson Innovative Medicine Korea said it received reimbursement for Balversa (erdafitinib), a treatment for ...
Posted by Michael Wonder on 04 Mar 2026
SpliSense granted EMA EARLY PRIME designation for SPL84 in cystic fibrosis
3 March 2026 - SpliSense today announced that the EMA has granted early Priority Medicines (e-PRIME) designation to SPL84 for ...